Sophia Ran

Dr. Sophia Ran received her Ph.D. degree in Biochemistry in 1989 from the Weizmann Institute in Israel. She completed postgraduate training in the University of Alabama at Birmingham, USA, and the Hospital for Sick Children, Canada. After working three years in a pharmaceutical company on developing anti-cancer drugs, she moved to the Southwestern Medical Center in Dallas, Texas, to develop new agents targeting tumor vessels. In 2003, she moved to Southern Illinois University where she is currently an Associate Professor in the Department of Medical Microbiology, Immunology and Cell Biology. Her major research interests are tumor vessels and metastasis. She is an author of 23 US and 69 international patents as well as 43 scientific papers related mainly to tumor angiogenesis, lymphangiogenesis, anti-cancer therapies and metastasis. Dr. Ran is a member of Research Advisory Board of American Cancer Society in the Illinois Division and an associate editor of Frontiers in Vascular Physiology, ISRN Oncology and OJPathology. She served as a grant reviewer for NIH, ACS, the US Army, the Cancer Research Council in England, the Italian Ministry of Health, the Swiss Cancer League and the Swiss National Foundation.

1books edited

Latest work with IntechOpen by Sophia Ran

Tumor angiogenesis is the main process responsible for the formation of new blood vessels that promote tumor growth and metastasis. This process is driven by potent pro-angiogenic factors that are predominant in the tumor environment and are produced by both malignant cells and the host cells recruited to the tumor site. Tumor environment is characterized by the imbalance between pro-angiogenic and anti-angiogenic factors, which drives the construction of numerous but structurally defective vessels. These poorly perfused and abnormal vessels significantly contribute to the tumor pathology not only by supporting the expansion of the tumor mass but also by promoting chronic inflammation, enhancing thrombosis, impeding drug delivery, and disseminating tumor cells. These problems associated with tumor vasculature continue to attract great attention of scientists and clinicians interested in advancing the understanding of tumor biology and development of new drugs. This book complies a series of reviews that cover a broad spectrum of current topics related to the pathology of tumor blood vessels including mechanisms inducing new vessels, identification of new targets for inhibition of tumor angiogenesis, and potential clinical use of known and novel anti-angiogenic therapies. The book provides an update on tumor angiogenesis that could be useful for oncologists, cancer researchers and biologists with interests in vascular and endothelial cell behavior in the context of cancer.

Go to the book